allulose stimulates glp 1 GLP-1 release and vagal afferent activation mediate the beneficial metabolic and chronotherapeutic effects of D-allulose GLP-1-based therapies for type 2

These difficulties have been partially alleviated throughout the past few years as a result of significant advancements in our knowledge of forms of ASD that are caused by single-gene abnormalities, such as tuberous sclerosis and fragile X syndrome

The current study encompassed all cases in which GLP-1RAs were administered and listed as primary suspect drugs, secondary suspect drugs, or concomitant drugs for SSIBs

C.BraasD.GoJ.et al (2018)

Tirzepatide (Mounjaro) : A dual-action medication that targets both GLP-1 and GIP receptors, demonstrating remarkable results in weight loss and glucose control

When we say the evidence shows this works, who was actually included in that evidence